April 19th 2024
Results published in the journal Ophthalmology find no risk reduction from daily one-gram capsules of omega-3 fatty acids.
Americans Show New Interest in Virtual Eye Care Options
February 11th 2021Young adults, in particular, are more likely to seek out and place high value on telemedicine for eye care and those in vulnerable populations are benefitting most, according to an annual vision wellness study by VersantHealth.
Read More
Impact of Vision Care, Specifically Diabetic Retinopathy, on Older Adults
October 30th 2020Falls are the current leading cause of injuries for older Americans, and many of them result in permanent disability and fatalities. The risk of falling for older adults doubles if they have impaired vision from a degenerative eye disease like diabetic retinopathy.
Read More
Time to Revise Hydroxychloroquine, Retinopathy Guidelines, Say Authors
October 21st 2020Rather than stopping hydroxychloroquine altogether, doses could be reduced and patients monitored if there are signs of retinopathy, say the authors of a commentary in the American Journal of Ophthalmology.
Read More
Headaches Behind the Eyes – Triggers, Treatments and How to Prevent Them
October 21st 2020Across the world, almost everyone has experienced a bad headache and knows the unpleasant symptoms that can come with it. Many have also faced migraines, which can cause dizziness, nausea and stomach pain - as well as impacting your vision.
Read More
FDA approves combination glaucoma drop without beta-blocker
April 23rd 2013FDA approved a new fixed-dose combination ophthalmic suspension of a carbonic anhydrase inhibitor (brinzolamide 1.0%) and an alpha 2 adrenergic receptor agonist (brimonidine tartrate 0.2%), which is indicated for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Read More
Ranibizumab and bevacizumab have equivalent effect on neovascular AMD
May 13th 2011Two of the most commonly used treatments for neovascular AMD, ranibizumab (Lucentis, Genentech), approved in 2006 by FDA, and the other commonly used ?off-label,? bevacizumab (Avastin, Genentech), resulted in similar improvements in visual acuity, according to a new randomized controlled trial published in NEJM.
Read More